The First International Symposium on Drugs Affecting Lipid Metabolism was held in Milan in 1960. In the succeeding symposia, as in the first, new data and new ideas emerged which stimulated further research in the field. The present volume comprises the proceedings of the Fifth Symposium. In the area of lipoproteins, we have progressed from descriptions of their chemistry to dis cus sion of their physiology and of their control of cholesterol metabolism at the cellular level. Workshop sessions explored thrombosis as affected by drugs, risk factors other than diet, animal models for atherosclerosis research and the organization of lipid clinics and clinical trials. All these topics represent advances in knowledge over the last decade. In the area of drugs a number of new compounds were introduced, many of them offer ing new structural concepts for hypocholesteremic activity. We expect that the next Symposium will offer as many new hypotheses and avenues of approach as did this one. We gratefully acknowledge the assistance of Dr. Sergio Gorini and the Lorenzini Foundation and the contributions of Drs. Cesare Sirtori and Remo Fumagalli all of which helped to assure the success of this Symposium. We also wish to thank Miss Jane T. Kolimaga for her assistance in the preparation of this volume. David Kritchevsky Rodol Pds. o Paoletti William L. Holme s vii CONTENTS Opening Remarks. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 W. L. Holmes CHEMISTRY AND PHYSIOLOGY OF LIPOPROTEINS The Interaction of Apolipoprotein-Alanine (ApoC-III) with Lipids: Study of Structural Features Required for Binding. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Inhalt
Opening Remarks.- Chemistry and Physiology of Lipoproteins.- The Interaction of Apolipoprotein-Alanine (ApoC-III) with Lipids: Study of Structural Features Required for Binding.- Lipoproteins and Lipid Transport.- Pathways of Lipoprotein Metabolism: Integration of Structure, Function and Metabolism.- Steroid Requirements for Suppression of HMG-CoA Reductase Activity in Cultured Human Fibroblasts.- The Immunology of Serum Lipoproteins.- Biochemical Pharmacology of Hypolipidemic Drugs.- Hormone-Induced Lipolysis and the Metabolic Pathways Providing Energy to the Cell: A Possible Role of ATP as a Rate-Limiting Factor.- Mechanism of Action of Hypolipidemic Drugs.- Newer Hypolipidemic Compounds.- Experimental and Clinical Evaluation of Two Atromid-S Analogues in Relation to Their Differential Modes of Action.- Approaches to Treatment of Hyperlipidemias.- Pathogenesis of Hyperlipidemias, Clues to Treatment?.- Serum Lipoprotein Composition in Different Types of Hyperlipoproteinemia.- Diet in the Management of Hyperlipidemic Patients.- The Partial Ileal Bypass Operation in Treatment of the Hyperlipidemias.- Drugs and Thrombosis.- The Activation and Inhibition of Fibrinolysis.- The Role of Lipids in the Tissue Factor Pathway of Blood Coagulation.- Use of Fibrinopeptide A Measurements in the Diagnosis and Management of Thrombosis.- Modifications of Platelet Functions by Dietary Fats.- Risk Factors Other than Diet.- Diabetes as a Risk Factor for Arteriosclerotic Vascular Disease.- Hypertension and Other Risk Factors.- The Heritable Hyperlipoproteinemias and Atherosclerosis.- Smoking and Carbon Monoxide Uptake as a Risk Factor in Atherosclerotic Cardiovascular Disease.- Risk of Coronary Disease and Coronary Complications by Neural and Psychological Factors.- Animal Models forAtherosclerosis Research.- New Animal Model for Atherosclerosis Research.- Effects of Various Hypolipidemic Drugs on Fatty Acid Composition of Liver and Serum Lipids.- Some Aspects of the Chimpanzee as a Model for Experimental Atherosclerosis.- Studies on Experimental Atherosclerosis by Immunofluorescence.- The Effects of Tolbutamide on the Development of Atherosclerosis in Rhesus Monkeys Fed an Average American Table-Prepared Diet.- The Cockerel as an Animal Model for Atherosclerosis Research.- Influence of Platelets on the Integrity of the Vessel Wall.- Scope and Organization of a Lipid Clinic and Clinical Trials.- Scope and Organization of a Lipid Clinic and Clinical Trials.- Portacaval Shunt in Two Patients with Homozygous Hypercholesterolemia.- Planning the Type II Coronary Primary Prevention Trial of the Lipid Research Clinics (U. S. A.).- Concluding Remarks.- Abstracts of Submitted Papers.- Author Index.